Q-omics provides the consensus-scored PRORY profile across patient tissues and cancer cell-line models. PRORY expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, PRORY is differentially expressed in 2, with the highest sampling consensus in LIHC. Additionally, PRORY RNA expression shows 3,766 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight BLCA, LIHC, and KIRC as cancer lineages where PRORY shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRORY — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRORY survival associations across molecular data types. PRORY RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRORY RNA expression–survival associations across cancer types. High PRORY expression shows unfavorable associations in LUAD, KIRC and KICH, but favorable associations in BLCA, STAD and ESCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .013). Together, the overview and detailed table identify BLCA as the clearest survival context for PRORY RNA expression.
This table summarizes PRORY tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for PRORY. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRORY shows higher tumor expression in LIHC and COAD. The LIHC box plot shows higher PRORY RNA expression in tumor versus normal tissue (log2 FC = +0.049, t-test p = .024).
This table shows molecular features associated with PRORY in patient tissues and cancer cell lines. In patient samples, PRORY shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set. In cancer cell lines, PRORY RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia.
